
    
      This is a phase II one arm study. Patients with HER2(Human Epidermal Growth Factor Receptor
      2) positive early stage breast cancer will receive ABI-007 and vinorelbine in combination
      with trastuzumab before having breast surgery.

      Approximately 50 patients will take part at multi-sites with potentially 20 patients
      participating at the Emory Winship Cancer Institute, Grady Memorial Hospital, and Emory
      Crawford Long Hospital in Atlanta, Georgia.
    
  